Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: A longitudinal study of protein kinetics throughout tumor progression and therapy

Journal of Clinical Oncology

Volumn 22, Issue 3, 2004, Pages 499-506

  Chan, Linda W ^a   Moses, Marsha A ^a   Goley, Elizabeth ^a   Sproull, Mary ^a   Muanza, Thierry ^a   Coleman, C Norman ^a   Figg, William D ^a   Albert, Paul S ^a   Ménard, Cynthia ^a   Camphausen, Kevin ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CREATININE; MATRIX METALLOPROTEINASE; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; URINE LEVEL; ADULT; AGED; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NEOPLASM; PREDICTION AND FORECASTING; URINE;

ADULT; AGED; CASE-CONTROL STUDIES; CREATININE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1442339457     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.022     Document Type: Article

References (31)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
2. Lindeholm B, Tavelin B, Grankvist K, et al: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16:3121-3128, 1998
3. Moses MA, Wiederschain D, Loughlin KR, et al: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395-1399, 1998
4. Kraft A, Weindel K, Ochs A, et al: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178-187, 1999
5. Smith BD, Smith GL, Carter D, et al: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18:2046-2052, 2000
6. Verheul HM, Hoekman K, Jorna AS, et al: Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation. Oncologist 5:45-50, 2000
7. Gerhards S, Jung K, Koenig F, et al: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57:675-679, 2001
8. Lengyel E, Schmalfeldt B, Konik E, et al: Expression of latent matrix metalloproteinase 9 predicts survival in advanced ovarian cancer. Gynecol Oncol 82:291-298, 2001
9. Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19:1207-1225, 2001
10. Cai W, Song JD: Expression of matrix metalloproteinase and tissue inhibitors in ovarian tumors. Ai Zheng 21:91-94, 2002
11. Kaban K, Herbst RS: Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am 16:1125-1171, 2002
12. Kausch I, Bohle A: Molecular aspects of bladder cancer: Prognostic markers of bladder cancer. Eur Urol 41:15-29, 2002
13. Kuittinen O, Soini Y, Turpeenniemi-Hujanen T: Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol 69:205-212, 2002
14. Ondruschka C, Buhtz P, Motsch C, et al: Prognostic value of MMP-2, -9 and TIMP-1, -2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract 198:509-515, 2002
15. Sienel W, Hellers J, Morresi-Hauf A, et al: Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 103:647-651, 2003
16. Mayerhofer M, Valent P, Sperr WR, et al: BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1a, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100: 3767-3775, 2002
17. Dvorak HF, Nagy JA, Berse B, et al: Vascular permeability factor, fibrin, and the pathogenesis of the tumor stroma formation. Ann N Y Acad Sci 667:110-111, 1992
18. Burke PA, DeNardo SA: Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol 39:155-171, 2001
19. Clark GM: Prognostic and Predictive Factors, in Harris JA, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast. Philadelphia, PA, Lippincott-Raven Publishers, 1996, pp 461-479
20. Van L, Borregaard N, Kjeldsen L, et al: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): Modulation of MMP-9 activity by NGAL. J Biol Chem 246:37258-37265, 2001
21. Agresti, A: Categorical Data Analysis. New York, NY, Wiley Press, 1990
22. Nakayama Y, Sako T, Shibao K, et al: Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 22:2437-2442, 2002
23. Hormbrey E, Gillespie P, Turner K, et al: A critical review of vascular endothelial growth factor analysis in peripheral blood: Is the current literature meaningful? Clin Exp Metastasis 19: 651-663, 2002
24. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378, 1999
25. Prestigiacomo AF, Lilja H, Pettersson K, et al: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: The best case scenario. J Urol 156:350-354, 1996
26. Coley CM, Barry MJ, Fleming C, et al: Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. Ann Intern Med 126:394-406, 1997
27. Einhorn N, Sjovall K, Knapp RC, et al: Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80:14-18, 1992
28. Carlson KJ, Skates SJ, Singer DE: Screening for ovarian cancer. Ann Intern Med 121:124-132, 1994
29. van der Schouw YT, Verbeek AL, Wobbes T, et al: Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma. Br J Cancer 66:148-154, 1992
30. Moertel CG, Fleming TR, Macdonald JS, et al: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270:943-947, 1993
31. Greenhalgh T: How to read a paper: Papers that report diagnostic or screening tests. BMJ 315:540-543, 1997